Published in Thorax on February 01, 2000
Comparison of Airway and Systemic Malondialdehyde Levels for Assessment of Oxidative Stress in Cystic Fibrosis. Lung (2015) 2.00
The role of heme oxygenase-1 in pulmonary disease. Am J Respir Cell Mol Biol (2006) 1.59
Heme oxygenase-1 and carbon monoxide in pulmonary medicine. Respir Res (2003) 1.33
Increased blood carboxyhaemoglobin concentrations in inflammatory pulmonary diseases. Thorax (2002) 1.02
Exhaled breath measures of inflammation: are they useful in neonatal chronic lung disease? Arch Dis Child Fetal Neonatal Ed (2005) 1.02
Effect of carbon monoxide on Mycobacterium tuberculosis pathogenesis. Med Gas Res (2012) 0.94
cor, a novel carbon monoxide resistance gene, is essential for Mycobacterium tuberculosis pathogenesis. MBio (2013) 0.86
Carbon monoxide in the treatment of sepsis. Am J Physiol Lung Cell Mol Physiol (2015) 0.85
Heme utilization by pathogenic bacteria: not all pathways lead to biliverdin. Acc Chem Res (2014) 0.85
Carbon monoxide in exhaled breath testing and therapeutics. J Breath Res (2013) 0.84
Noninvasive effects measurements for air pollution human studies: methods, analysis, and implications. J Expo Sci Environ Epidemiol (2015) 0.79
Assessment of airway inflammation with exhaled NO measurement. Hippokratia (2007) 0.77
Multicomponent Breath Analysis With Infrared Absorption Using Room-Temperature Quantum Cascade Lasers. IEEE Sens J (2009) 0.75
Normal values of exhaled carbon monoxide in healthy subjects: comparison between two methods of assessment. BMC Pulm Med (2014) 0.75
Diagnostic value of exhaled carbon monoxide as an early marker of exacerbation in children with chronic lung diseases. ISRN Pediatr (2012) 0.75
Exhaled carbon monoxide concentration is not elevated in patients with inflammatory bowel disease. Clin Exp Med (2007) 0.75
Increased nitric oxide in exhaled air of asthmatic patients. Lancet (1994) 5.39
Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci U S A (1997) 4.74
Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol (1996) 3.49
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med (1994) 3.24
Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat Med (1996) 3.12
Total sputum nitrate plus nitrite is raised during acute pulmonary infection in cystic fibrosis. Am J Respir Crit Care Med (1998) 1.84
Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J (1995) 1.80
Nitric oxide metabolites in cystic fibrosis lung disease. Arch Dis Child (1998) 1.76
Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J (1998) 1.72
Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest (1998) 1.71
Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol (1997) 1.68
Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med (1995) 1.67
Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax (1998) 1.63
Nitric oxide and airway disease. Ann Med (1995) 1.35
Nitrite levels in breath condensate of patients with cystic fibrosis is elevated in contrast to exhaled nitric oxide. Thorax (1998) 1.34
Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol (1998) 1.34
Increased carbon monoxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med (1997) 1.26
Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. Eur Respir J (1996) 1.24
Airway nitric oxide in asthmatic children and patients with cystic fibrosis. Eur Respir J (1996) 1.24
Lung infections. 3. Pseudomonas aeruginosa and other related species. Thorax (1998) 1.08
Role of free radicals in the pathogenesis of cystic fibrosis. Thorax (1994) 1.08
Increased carbon monoxide in exhaled air of subjects with upper respiratory tract infections. Am J Respir Crit Care Med (1998) 1.03
Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. Thorax (1998) 0.99
Surfactant composition in infants and young children with cystic fibrosis. Am J Respir Crit Care Med (1997) 0.97
Increased levels of nitric oxide derivatives in induced sputum in patients with asthma. J Allergy Clin Immunol (1997) 0.96
Increased carbon monoxide in exhaled air of patients with cystic fibrosis. Thorax (1999) 0.94
Enhanced oxidative damage in cystic fibrosis patients. Biofactors (1998) 0.86
Basic therapies in cystic fibrosis. Does standard therapy work? Clin Chest Med (1998) 0.80
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Medical student selection: a tentative attempt to establish a code of practice. Br Med J (1980) 7.21
Lymphocyte transformation in vitro measured by tritiated thymidine uptake. I. Lymphocyte culture techniques. Int Arch Allergy Appl Immunol (1970) 5.67
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med (1996) 5.53
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med (2001) 5.47
Increased nitric oxide in exhaled air of asthmatic patients. Lancet (1994) 5.39
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J (2005) 5.24
Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science (2000) 4.48
Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) (1998) 4.31
Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci U S A (1998) 4.28
Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature (1991) 3.86
Consultation length and outcome in two group general practices. J R Coll Gen Pract (1983) 3.76
Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med (1995) 3.61
Brief report: fulminating fat embolism syndrome caused by paradoxical embolism through a patent foramen ovale. N Engl J Med (1993) 3.55
Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet (2001) 3.48
Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med (1999) 3.44
Identification of the cystic fibrosis gene. BMJ (1990) 3.28
Independent genetic determinants of pancreatic and pulmonary status in cystic fibrosis. Lancet (1990) 3.27
Asthma as an axon reflex. Lancet (1986) 3.26
Single-dose slow-release aminophylline at night prevents nocturnal asthma. Lancet (1982) 3.21
Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol (1996) 3.20
Exhaled markers of pulmonary disease. Am J Respir Crit Care Med (2001) 3.14
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J (2000) 3.14
Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 3.13
Q fever endocarditis treated with trimethoprim and sulphamethoxazole. Br Med J (1972) 3.06
Neural control of human airways in health and disease. Am Rev Respir Dis (1986) 2.97
Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol (2001) 2.94
Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet (1981) 2.87
Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J (1997) 2.79
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax (1998) 2.71
The relationship of phenotype changes in Pseudomonas aeruginosa to the clinical condition of patients with cystic fibrosis. Am Rev Respir Dis (1983) 2.68
Exacerbations of chronic obstructive pulmonary disease. Eur Respir J (2007) 2.65
Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis (1987) 2.64
Cytokines in asthma. Thorax (1999) 2.64
High-dose beclomethasone inhaler in the treatment of asthma. Lancet (1983) 2.58
Paper and people: the work of the casualty reception clerk. Sociol Health Illn (1989) 2.54
Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax (2001) 2.50
Cystic fibrosis in adolescents and adults. Thorax (1987) 2.47
Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet (1986) 2.41
Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax (1983) 2.35
Prospective analysis of stoma-related complications. Colorectal Dis (2005) 2.35
Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med (1991) 2.34
Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med (2000) 2.33
Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med (1996) 2.32
Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med (1992) 2.32
Disappointing sensitivity of endoscopic markers for villous atrophy in a high-risk population: implications for celiac disease diagnosis during routine endoscopy. Am J Gastroenterol (2001) 2.30
The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock. J Exp Med (1997) 2.28
Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med (1995) 2.28
Circulating catecholamines in exercise and hyperventilation induced asthma. Thorax (1981) 2.22
Exhaled carbon monoxide in childhood asthma. J Pediatr (1999) 2.19
Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med (1998) 2.19
Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J (2001) 2.18
Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J (2004) 2.18
Evaluation of the forced expiration technique as an adjunct to postural drainage in treatment of cystic fibrosis. Br Med J (1979) 2.15
Transduction and rearrangement of the myc gene by feline leukaemia virus in naturally occurring T-cell leukaemias. Nature (1984) 2.14
A prognostic model for the prediction of survival in cystic fibrosis. Thorax (1997) 2.10
STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J (2004) 2.06
Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor. Nature (1993) 2.04
Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J (2002) 2.04
Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med (2000) 2.03
RCPE UK consensus statement on diabetes. J R Coll Physicians Edinb (2010) 2.03
Meconium ileus equivalent in adults with cystic fibrosis of pancreas: a report of six cases. Br Med J (1976) 2.02
Management of pneumothorax in adults with cystic fibrosis. Thorax (1982) 1.99
The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br J Pharmacol (1985) 1.98
Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun (2004) 1.98
Comparison of sevoflurane and propofol with rocuronium for modified rapid-sequence induction of anaesthesia. Anaesthesia (1999) 1.98
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med (1999) 1.96
Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun (1994) 1.96
Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.94
Prevalence of celiac disease and its endoscopic markers among patients having routine upper gastrointestinal endoscopy. Am J Gastroenterol (1999) 1.93
Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med (1999) 1.92
Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med (1997) 1.91
A calcium antagonist, nifedipine, modifies exercise-induced asthma. Thorax (1981) 1.90
Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis (1985) 1.89
T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol (2009) 1.89
Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med (1995) 1.84
A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med (1997) 1.84
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J (1995) 1.80
Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J Mol Biol (2000) 1.78
Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM (1996) 1.78
Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol (1999) 1.77
Brittle asthma. Thorax (1998) 1.77
Importance of inhaler devices in the management of airway disease. Respir Med (2007) 1.76
Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax (2001) 1.76
Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour. Thorax (1982) 1.76
Novel ribosomal mutations affecting translational accuracy, antibiotic resistance and virulence of Salmonella typhimurium. Mol Microbiol (1999) 1.75
Long term venous access using a totally implantable drug delivery system in patients with cystic fibrosis and bronchiectasis. Respir Med (1989) 1.75
Airway inflammation after controlled exposure to diesel exhaust particulates. Am J Respir Crit Care Med (2000) 1.75